GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (NAS:FBIO) » Definitions » Shiller PE Ratio

Fortress Biotech (Fortress Biotech) Shiller PE Ratio : (As of May. 14, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Fortress Biotech Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Fortress Biotech Shiller PE Ratio Historical Data

The historical data trend for Fortress Biotech's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortress Biotech Shiller PE Ratio Chart

Fortress Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Fortress Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Fortress Biotech's Shiller PE Ratio

For the Biotechnology subindustry, Fortress Biotech's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fortress Biotech's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's Shiller PE Ratio falls into.



Fortress Biotech Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Fortress Biotech's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Fortress Biotech's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.526/129.4194*129.4194
=-0.526

Current CPI (Dec. 2023) = 129.4194.

Fortress Biotech Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -3.150 99.695 -4.089
201406 -1.950 100.560 -2.510
201409 -1.950 100.428 -2.513
201412 -1.500 99.070 -1.960
201503 -4.650 99.621 -6.041
201506 -2.400 100.684 -3.085
201509 -6.900 100.392 -8.895
201512 -4.650 99.792 -6.031
201603 -4.650 100.470 -5.990
201606 -4.650 101.688 -5.918
201609 -4.800 101.861 -6.099
201612 -6.600 101.863 -8.385
201703 -4.500 102.862 -5.662
201706 -6.450 103.349 -8.077
201709 -10.050 104.136 -12.490
201712 -3.300 104.011 -4.106
201803 -7.350 105.290 -9.034
201806 -7.500 106.317 -9.130
201809 -5.550 106.507 -6.744
201812 -8.700 105.998 -10.622
201903 0.300 107.251 0.362
201906 -3.600 108.070 -4.311
201909 -3.300 108.329 -3.942
201912 -4.050 108.420 -4.834
202003 -2.850 108.902 -3.387
202006 -2.850 108.767 -3.391
202009 -3.000 109.815 -3.536
202012 -0.900 109.897 -1.060
202103 -1.650 111.754 -1.911
202106 -0.600 114.631 -0.677
202109 -3.900 115.734 -4.361
202112 -5.700 117.630 -6.271
202203 -2.700 121.301 -2.881
202206 -3.900 125.017 -4.037
202209 -4.112 125.227 -4.250
202212 -4.814 125.222 -4.975
202303 -3.150 127.348 -3.201
202306 -3.600 128.729 -3.619
202309 -0.940 129.860 -0.937
202312 -0.526 129.419 -0.526

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Fortress Biotech  (NAS:FBIO) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Fortress Biotech Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Fortress Biotech's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Fortress Biotech (Fortress Biotech) Business Description

Traded in Other Exchanges
Address
1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.
Executives
Rosenwald Lindsay A Md director, 10 percent owner, officer: PRESIDENT, CEO & CHAIRMAN 375 PARK AVE, NEW YORK NY 10152
Lucy Lu director THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
David Jin officer: Chief Financial Officer C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036
Dov Klein director C/O FORTRESS BIOTECH, INC., 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
Robyn Hunter officer: Chief Financial Officer 95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453
Eric K Rowinsky director IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Malcolm Hoenlein director 750 LEXINGTON AVENUE, NEW YORK NY 10022
Michael S Weiss director, 10 percent owner, officer: EXECUTIVE VICE CHAIRMAN 750 LEXINGTON AVE, NEW YORK NY 10022
J Jay Lobell director 365 W END AVE, APARTMENT 10A, NEW YORK NY 10024
Jimmie Harvey director 3741 EAST FAIRWAY DRIVE, BIRMINGHAM AL 35213
Kevin Lorenz director C/O NUVEEN, 333 W. WACKER DR., CHICAGO IL 60606
George Avgerinos officer: SVP, Biologics Operations C/O CORONADO BIOSCIENCES, INC., 24 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Kevin Horgan other: Former Chief Medical Officer C/O SOLIGENIX, INC., 29 EMMONS DRIVE, STE. C-10, PRINCETON NJ 08540
David Jonathan Barrett director ONE PENN PLAZA, SUITE 2514, NEW YORK NY 10119
Harlan F Weisman director C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803

Fortress Biotech (Fortress Biotech) Headlines

From GuruFocus

Is Fortress Biotech Inc Undervalued Following the Latest Insider Buy?

By GuruFocus Research GuruFocus Editor 10-24-2022